NCCN Imaging Appropriate Use Criteria endorsed by Intermountain Healthcare

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Intermountain Healthcare has endorsed the NCCN Imaging Appropriate Use Criteria.

NCCN and Intermountain are both recognized by Centers for Medicare & Medicaid Services as approved provider-led entities for development of imaging AUC. Intermountain will aggregate the NCCN AUC for lung cancer with its own AUC and utilize the content for decision support.

Intermountain is one of the largest hospital systems in the United States, serving patients across Utah, Southeastern Idaho, and the surrounding area.

“This agreement with Intermountain helps ensure patients throughout the mountain region are receiving the best, most up-to-date treatment,” said Robert Carlson, CEO of NCCN. “The NCCN Imaging AUC is designed as a reference that can be integrated into the appropriate use criteria already in place at Intermountain. By working with a system that includes both large hospitals and community health clinics, we can make sure that the best care is available to patients regardless of location or circumstances.”

Derived from the NCCN Clinical Practice Guidelines in Oncology, the NCCN Imaging AUC supports clinical decision-making around the use of imaging in patients with cancer by outlining all imaging procedures recommended in the NCCN Guidelines®, including radiographs, computed tomography scans, magnetic resonance imaging, functional nuclear medicine imaging, and ultrasound.

YOU MAY BE INTERESTED IN

In an effort to target the right patients, genetic screening is becoming more common in clinical trials. But incorporating it can be complex and add a significant burden for both patients and clinical trial sites. Genetic counseling can streamline that process and help drug and gene therapy developers expedite the recruitment of genetically-eligible participants for their trials and use genetic testing results to accelerate the speed and success of clinical trials.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login